Thu-07-01-2016, 20:52 PM
(Thu-07-01-2016, 20:37 PM)Fred Wrote:(Thu-07-01-2016, 20:26 PM)jiml Wrote:(Thu-07-01-2016, 20:11 PM)Fred Wrote: That reminds me I don't know if it is of interest to the DMF gang but I asked my dermatologist how the trial on Fumaderm went at my hospital in France.
It has been dropped and will not be made available under the French health care system.. She didn't say exactly why, but it seems by what I could work out it was dropped in favour of accepting Otezla and Cosentyx.
How strange on price alone I would think fumaderm would be a good choice it's far cheaper than either of the other two otezla and cosentyx
I'm sure there are other reasons because it's far less harmful than methotrexate and in my opinion safer than biological drugs
I couldn't get any more from her Jim. My knowledge of the French system is that they don't tend to judge by cost as they have a very healthy budget, so I'm guessing it must have been the results from their own tests that gave them their decision. They maybe look at clearance times or how many people drop out of a test. You guess is as good as mine. It could be they can only bring in so many new treatments per year I don't know, but she gave me the impression it will never be available in France.
I suppose it's better than the way the UK are doing it. As you know some can get it but other parts of the country have no chance, is that the way the UK test it?
Here I think it's up to the individual dermatologist I think.. To put a case to the head of dermatology and I think rather than make waves they just go with the flow.
I will try to find more out next Friday when I am at the teaching hospital (as a patient) not a doctor but I can have a word with the consultants there and see what their thinking is